Clearly, a decline in patient dependence on a developer’s drug would marginally mean less profits for that particular company. This would, of course, concern the developer and they would need to pursue measures to convince patients to be dependent on their drug again. Such measures could be decreasing their drug’s marketed price by direct price decrease, providing discounts, or making it completely
Clearly, a decline in patient dependence on a developer’s drug would marginally mean less profits for that particular company. This would, of course, concern the developer and they would need to pursue measures to convince patients to be dependent on their drug again. Such measures could be decreasing their drug’s marketed price by direct price decrease, providing discounts, or making it completely